Company: VRCA
Filing Date: 2025-03-11
Form Type: S-3
Source: 0001193125-25-052031
Chunk: 9

Company: Verrica Pharmaceuticals Inc.
Filing Date: 2025-03-11
Form: S-3
Chunk 9
---
 • |     | conversion or exchange prices or rates, if any, and, if applicable, any provisions for changes to or adjustments              
 in the conversion or exchange prices or rates and in the securities or other property receivable upon conversion or exchange; |

| • |     | ranking; |

| • |     | restrictive covenants, if any; |

| • |     | voting or other rights, if any; and |

| • |     | material or special U.S. federal income tax considerations, if any. |

The applicable prospectus supplement and any related free writing prospectuses that we may authorize to be provided to you may also add, update or change any of the information contained in this prospectus or in the documents we have incorporated by reference. However, no prospectus supplement or free writing prospectuses will offer a security that is not registered and described in this prospectus at the time of the effectiveness of the registration statement of which this prospectus is a part. This prospectus may not be used to consummate a sale of securities unless it is accompanied by a prospectus supplement. We may sell the securities directly to investors or through underwriters, dealers or agents. We and our agents, underwriters or dealers reserve the right to accept or reject all or part of any proposed purchase of securities. If we do offer securities through agents, underwriters or dealers we will include in the applicable prospectus supplement:

| • |     | the names of those agents, underwriters or dealers; |

| • |     | applicable fees, discounts and commissions to be paid to them; |

| • |     | details regarding over-allotment options, if any; and |

| • |     | the estimated net proceeds to us. |

Common Stock. We may issue shares of our common stock from time to time. Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders and do not have cumulative voting rights. An election of directors by our stockholders shall be determined by a plurality of the

3

votes cast by the stockholders entitled to vote on the election. Holders of common stock are entitled to receive ratably any dividends as may be declared by our board of directors, subject to any
preferential dividend rights of any series of preferred stock that we may designate and issue in the future.

In the event of our liquidation, dissolution
or winding up, the holders of common stock are entitled to receive ratably our net assets available